Index

Page numbers in *italics* refer to illustrations; those in **bold** refer to tables

A-317491 102
abdominal examination 37
acetylcholine 10, 85–86
  botulinum neurotoxin effect 166–168
  *see also* anticholinergic therapy
acupuncture 130–131, 156
ADAM study 121
Aδ-fibers 4, 11
AF-353 102–103
age-related changes *see* older patients
alcohol consumption 69, 74
alfuzosin 124
alpha-blockers
  co-medication with antimuscarinics 119–122, 120, 122
  co-medication with phosphodiesterase-5 inhibitors 122
  male bladder outlet obstruction therapy 227
Alzheimer’s disease therapy 210
ambulatory urodynamic monitoring (AUM) 51
AMTB 109–110, 111
anandamide 103, 104
animal models 13–15
  experimental auto-immune encephalomyelitis (EAE) 14–15, 15
  multiple system atrophy (MSA) 15
Parkinson disease 14
spinal cord injury 13–14
anticholinergic therapy 26–27
  adverse effects 91–92
  cholinesterase inhibitor interaction 210
  older patients 211–212
  *transdermal (TD) delivery* 91–98
  *see also* antimuscarinics
  antidepressants 89
  antimuscarinics 85–87
  adverse effects 86–87
  bladder outlet obstruction and 229
  co-medication 119–122, 120, 122, 125–126
    botulinum neurotoxin interaction 171, 179
  compliance 87
  evidence for efficacy 87
  important properties 86
  *transdermal (TD) delivery* 91–98
  *see also* anticholinergic therapy
  2-arachidonoylglycerol 103
  artificial sweeteners 69, 75
  artificial urethral sphincter 196
  augmentation cystoplasty 191–197
  artificial urethral sphincter insertion 196
  complications 196–197
  enterocystoplasty 191–195, 192, 194, 195
  post-augmentation urodynamic studies 195–196
  seromuscular enterocystoplasty 198, 199
  ureteric reimplantation 194
autonomic nervous system 57–58
back pain 35
bacteriuria, following augmentation cystoplasty 197
Ba-Wei-Die-Huang-Wan 131
behavioral management *see* lifestyle changes
benign prostatic hyperplasia (BPH) 119, 222–223
see also bladder outlet obstruction (BOO)
beta, adrenergic receptors 10
agonists 89
biomarkers 54–56
brain-derived neurotrophic factor (BDNF) 55
C-reactive protein 56
cytokines and chemokines 56
 genetic biomarkers 56
nerve growth factor (NGF) 55
prostaglandins 55–56
bladder
compliance 46
denervation procedures 198–199
detrusor leak point pressure (DLPP) 46–47
filling cystometry 45–47
incomplete emptying 32
innervation 10–11
 afferent neuron plasticity 14
maximum capacity 46
pain 31, 46
 sacral nerve stimulation benefits 145
sensation 45–46
 absent 46
 increased 46
 normal 45–46
 reduced 46
bladder augmentation 191–198
detrusor myectomy
 autoaugmentation 197–198, 198
see also augmentation cystoplasty
bladder cooling reflex (BCR) 109
bladder outlet obstruction (BOO) 222, 223–224
antimuscarinics and 229
overactive bladder relationship 224–226, 227
pressure–flow studies 50, 223–224, 224, 233
treatment 227–229
 α-blockers 227
surgery 227–229
women 225
bladder training 77–78, 129–130
clinical recommendations 78
evidence 77–78
rationale 77
bladder wall strain imaging 57
bladder wall thickness (BWT) 53–54
body mass index (BMI) 66
botulinum neurotoxin type A (BoNT/A) 165–166, 165
cost-effectiveness 181
effects when injected into the bladder 166–168, 167
idiopathic detrusor overactivity management 175–181
adverse effects 180–181
antimuscarinic interaction 179
dosage 178–179
efficacy 175–178, 176, 177
injection technique 180
onset and duration of effect 178
predictors of response 179–180
quality of life impact 179
mechanisms of action 166–168
neurogenic detrusor overactivity management 168–175
antimuscarinic interaction 171
bladder injection technique 173–174, 174
dilution 173
dosage 172–173
efficacy 168–172, 169, 170
onset and duration of effect 170–171
predictors of response 171
quality of life impact 172
safety issues 174–175
older patients 215–216
bowel symptoms
 constipation 34, 69–70
following augmentation cystoplasty 197
brain
 functional changes in older patients 207–208
functional imaging 58, 207
micturition regulation 8–9, 9
brain-derived neurotrophic factor (BDNF) 55
caffeine intake 68, 74–75
 caffeine content of foods and drugs 73
 older patients 211
cannabinoids 103–105
 clinical trials 105
micturition and 104–105
receptor agonist effects 104–105
receptor distribution 103–104
side effects 105
cannabinor 105
capsaicin 106
capsazepine 110
catheterization 133
C-fibers 4, 11
C-fiber reflex 18
chemokines 56
cholinesterase inhibitors (CEI) 210
citrus juice intake 68, 75
clam ileocystoplasty 192–193, 192, 196
coital incontinence 33
co-morbidity, older patients 208, 208
compliance, bladder 46
conservative treatment 26
  limitations of 142–143
  older people 210–211
  see also lifestyle changes; medical treatment; physical therapy
constipation 34, 69–70
  avoidance of 75
  straining 69–70
containment products 132–133
costs of overactive bladder 5
coughing 67
C-reactive protein 56
cystolysis 199
cystometry see filling cystometry
cystoplasty see augmentation cystoplasty
cystourethropexy patients, sacral nerve
  stimulation 146
cytokines 56
darifenacin 88–89
  older patients 213
defecation, straining 69–70
dehydration, older patients 211
  see also fluid intake management
dementia therapy 210
denervation hypersensitivity theory 226
denervation procedures 198–199
detrusor
  histological changes 16
  normal function 47
detrusor leak point pressure (DLPP) 46–47
detrusor myectomy
  autoaugmentation 197–198, 198
detrusor overactivity (DO) 7
  during filling cystometry 47, 48
  overactive bladder relationship 49
  patterns of 47
detrusor-sphincter dyssynergia 13
detrusor wall thickness (DWT) 53–54
diabetes insipidus 36
diabetes mellitus 35
dietary factors
  bladder irritants 68–69, 74–75
  constipation avoidance 69–70, 75
doxazosin 121–122
doxepin 89
drug history 36
drug therapy see medical treatment
duloxetine 89
dysuria 33–34
elderly patients see older patients
electrical stimulation 80–81
encephalomyelitis, experimental
  auto-immune 14–15, 15
endocannabinoid system 103
  see also cannabinoids
enterocystoplasty 191–195, 192, 194, 195
  contraindications 194
  seromuscular enterocystoplasty 198, 199
  see also augmentation cystoplasty
EP-1 receptor antagonists 101
erectile dysfunction (ED) 122–123
estrogen, topical therapy 37
evaluation
  autonomic nervous system 47–48
  biomarkers 54–56
  bladder/detrusor wall thickness 53–54
  bladder wall strain imaging 57
  examination 36–39
  functional brain imaging 58
  history taking 29–36
  near infrared spectroscopy (NIRS) 57
  questionnaires 39–40
  timing of evaluation 25–27
  see also urodynamics
exercise benefits, older people 208, 211
  see also pelvic floor exercises
exocannabinoid therapy see cannabinoids
experimental auto-immune encephalomyelitis
(EAE) model 14–15, 15
fatty acid amide hydrolase (FAAH) 103
inhibitor effects 1–5
fesoterodine 88
older patients 213–214
filling cystometry 45–48
bladder sensation during 45–47
detrusor function during 47
overactive bladder during 47–48
fluid intake management 67–68, 73–74
older patients 211
frailty 206
frequency 30
functional brain imaging 58
gel treatment see transdermal (TD) drug delivery
gene therapy 133–134
genetic biomarkers 56
geriatric patients see older patients
Gosha-jinki-gan (GJG) 131
GRC 6211 110
growth factors 55, 56
gynecological examination 37
gynecological history 35
health related quality of life (HRQoL) 39, 206
herbal remedies 131–132
hesitancy 31
histological changes 16–18
detrusor 16
lamina propria 16–18, 17
neuronal structure 18
older patients 207
urothelium 16
history taking 29–36
drug history 36
dysuria 33–34
gynecological history 35
incontinence symptoms 32–33
medical/surgical history 36
neurological history 34–35
nocturnal enuresis 33
obstetric history 35–36
prolapase symptoms 34
storage symptoms 30–31
voiding symptoms 31–32
hypogastric nerve 10
idiopathic detrusor overactivity (IDO) 7
ileocystoplasty 191–193, 192
Goodwin cup-patch technique 193, 194
see also augmentation cystoplasty
imipramine 89
incomplete bladder emptying 32
incontinence 3
coital incontinence 33
history taking 32–33
mixed incontinence 33
stress urinary incontinence 33
urgency urinary incontinence 33
Ingleman-Sundberg denervation 198
innervation of the bladder
central 8–10
brain 8–9, 9
spinal cord 9–10
peripheral 10–11
integrative hypothesis 12
intermittent flow 32
interstitial cystitis (IC), sacral nerve stimulation 145
K-channel openers 101
lamina propria, histological changes 16–18, 17
leiomyoma 35
lifestyle changes 65–66
constipation avoidance 69–70, 75
dietary factors 68–69, 74–75
evidence and recommendations 74
fluid intake management 67–68, 73–74
older people 210–211
smoking cessation 67, 73
weight management 66–67, 73
long latency somatosensory evoked potentials
(LL-SEP) 158
magnetic stimulation 132
male patients 222–223
male patients (cont’d)
benign prostatic hyperplasia (BPH) 119, 222–223
bladder outlet obstruction (BOO) 233–234
antimuscarinics and 229
medical treatment 227
overactive bladder relationship 224–226, 227
pressure–flow studies 50, 223–224, 224, 233
surgical treatment 227–229
coco-medication 119–126
antimuscarinic/α-adrenoreceptor antagonist 119–122
phosphodiesterase-5 inhibitor/α-adrenoceptor antagonist 122–125
erectile dysfunction (ED) 122–123
management algorithm 123
overactive bladder pathogenesis 225–226, 227
management
containment products 132–133
future therapies 133–134
individualization 27
initial management 233–235
patients failing initial management 235–237
specialist referral 27, 27
treatment algorithm 150–152, 151, 236
see also specific therapies
Maxi-K therapy 101
medical history 36
medical treatment
α-blockers 119–125
anticholinergics 26–27
antidepressants 89
antimuscarinics 85–89, 119–122
β3 adrenergic receptor (AR) agonists 89
cannabinoid system as target 103–105
coco-medication 118–126
future drugs and targets 101
older patients 211–212
oral agents 86
P2X, receptor antagonists 101–103
phosphodiesterase-5 inhibitors 122–125
transdermal delivery 91–98
see also medications; specific drugs
medications
drug history 36
medications which may worsen urinary incontinence 209
polypharmacy in older patients 208–209
see also medical treatment; specific drugs
men see male patients
micturition cycle regulation 8–9, 9
mirabegron 89
older patients 215
mixed urinary incontinence 33, 43
multi-morbidity, older patients 208, 208
multiple sclerosis (MS) 14
sacral nerve stimulation 145
multiple system atrophy (MSA), animal model 15
myogenic hypothesis 11–12
naturopathic remedies 131–132
near infrared spectroscopy (NIRS) 57
nerve growth factor (NGF) 55, 100
neurogenic detrusor overactivity (NDO) 7
integrative hypothesis 12
myogenic hypothesis 11–12
neurogenic hypothesis 11
neurological examination 36–37
neurological history 34–35
neuromodulation 141, 154–155, 155
clinical need for 141
history 158
mechanism 157–158
see also posterior tibial nerve stimulation (PTNS); sacral nerve stimulation (SNS)
nociception 3, 30–31
nocurnal enuresis 33, 146
non-adrenergic, non-cholinergic (NANC) neurotransmitters 10–11
obesity 66–67
weight management 66–67, 73
obstetric history 35–36
older patients 25–27, 205–206
conservative therapies 210–211
frailty 206
lifestyle and behavioral changes 210–211
multi-morbidity 208, 208
overactive bladder pathophysiology 206–208
pharmacological intervention
botulinum toxin 215–216
darifenacin 213
fesoterodine 213–214
mirabegron 215
propiverine hydrochloride 215
solifenacin 214
tolterodine 213
trospium chloride 214–215
pharmacological interventions 211–212
oxybutynin 212
polypharmacy 208–209
onabotulinumtoxinA see botulinum neurotoxin type A (BoNT/A)
overactive bladder (OAB) 25–26, 44
bladder outlet obstruction relationship in men 224–225
pathogenesis 225–226, 227
detrusor overactivity relationship 49
economic costs of 5
prevalence 5, 25, 141–142
quality of life impacts 142, 206
refractory 143
terminology 3–5
oxybutynin 87, 92
adverse effects 87, 92, 97
co-medication 121
older patients 212
rationale for transdermal delivery 91–92
 topical gel 94–97, 97
efficacy 94–96, 95–96
quality of life impact 97
safety 96, 97
skin tolerability 96–97
transdermal patch 92–94, 93
efficacy 93
tolerability 93–94

P2X₃ receptors 101–103
antagonists 102–103
pain
back 35
bladder 31, 46
sacral nerve stimulation benefits 145
dysuria 33–34
parasympathetic innervation 10
Parkinson disease, animal model 14
patches see transdermal (TD) drug delivery
pathophysiology
integrative hypothesis 12
lesion location significance 12–13, 12
male patients, bladder outlet obstruction relationship 225–226, 227
myogenic hypothesis 11–12
neurogenic hypothesis 11
older patients 206–208
pediatric patients, sacral nerve stimulation 146
pelvic floor exercises 26, 78–80
 evidence 79–80
rationale 78–79
recommendations 80
pelvic nerve 10
pelvic organ prolapse 31, 37–38
symptoms 34
percutaneous nerve evaluation (PNE) 147
peripheral innervation 10–11
peripheral lesions 13
pharmacotherapy see medical treatment
phenol injection 198
phosphodiesterase-5 (PDE5) inhibitors 122–125
physical therapy 76–77
acupuncture 130–131
bladder training 77–78, 129–130
electrical stimulation 80–81
magnetic stimulation 132
pelvic floor muscle training 78–80
polypharmacy, older patients 208–209
pontine micturition center (PMC) 8–9
posterior tibial nerve stimulation (PTNS) 154
clinical results 158–160
future perspectives 161–162
mechanism 157–158
prognostic factors 160
technique 157
Urgent-SQ implant 160–161, 161, 162
post-micturition dribble 32
pressure–flow studies (PFS) 49–51
bladder outlet obstruction 50, 223–224, 224, 233
prevalence 5, 25, 141–142
prolapse symptoms see pelvic organ prolapse
propiverine 121–122
older patients 215
prostaglandins 55–56
PGE2 101
pudendal nerve 10
quality of life (QoL) 39, 142  
botulinum neurotoxin injection impact 172  
oxybutynin topical gel impact 97  
questionnaires 39–40  
rectal examination 37, 39  
Rho kinase inhibition 101  
sacral nerve stimulation (SNS) 143–152  
  complications 144, 150  
  contraindications 145  
  MRI and 145  
  outcomes 144–145  
  technique 147–149, 147, 148  
  troubleshooting 149–150  
sacral rhizotomy 198  
scheduled voiding see bladder training  
sciatic nerve 155  
Self-Assessment Goal Achievement (SAGA) questionnaire 40  
seromuscular enterocystoplasty 198, 199  
short latency somatosensory evoked potentials (SL-SEP) 158  
sigmoid augmentation cystoplasty 195, 195  
sildenafil 124  
smoking 67, 73  
soda intake 68  
solfenacin 88, 121  
  older patients 214  
somatosensory evoked potentials  
  long latency (LL-SEP) 158  
  short latency (SL-SEP) 158  
specialist referral 27, 27  
sphincter see urethral sphincter  
spiced foods 69, 75  
spinal cord injury (SCI)  
  animal model 13–14  
  sacral nerve stimulation 145  
  spinal cord plasticity 14  
spinal cord, role in micturition regulation 9–10  
storage symptoms 30–31  
  bladder pain 31  
  frequency 30  
  nocturia 30–31  
  urgency 31  
  straining 31  
  on defecation 69–70  
stress incontinence 33  
SUmiT trial 159  
suprapontine lesions 12–13  
suprasacral-infrapontine lesions 13  
surgical history 36  
sympathetic innervation 10  
tadalafil 124  
tamsulosin 119–121, 124–125  
TIMES study 119–120  
tissue engineering 133–134  
tolterodine 88, 119–121  
  older patients 213  
tomatoes 69, 74  
transdermal (TD) drug delivery 91–98  
  adverse effects 94, 96–97, 97  
  oxybutynin topical gel (OTG) 94–97, 95–96  
  oxybutynin transdermal patch 92–94, 93  
  rationale 91–92  
transurethral resection of the prostate (TURP) 228–229  
treatment algorithm 150–152, 151, 236  
  see also management  
tricyclic antidepressants 89  
trospium 87–88  
  older patients 214–215  
TRP channels 105–106  
  overactive bladder and 111–112  
TRPA1 105, 108–109  
TRPM8 105, 109–112  
  antagonists 111  
TRPV1 103–107, 111  
  antagonists 110  
  capsaicin effect 106  
TRPV2 105, 107  
TRPV4 105, 107–108  
  antagonists 110–111  
umbrella cells 16  
ureteric reimplantation 194  
urethral sphincter 10, 11  
  artificial sphincter insertion with bladder  
  augmentation 196  
  overactivity 8  
urethral support, loss of 37–38  
urge 4  
urge incontinence 3
urgency 3, 31, 46
  versus urge 4
urgency incontinence 33
Urgent-SQ implant 160–161, 161, 162
urinary diversion 200
urinary tract infections
  following botulinum neurotoxin injection 180
  following enterocystoplasty 193
urodynamics 43–51
  ambulatory urodynamics 51
  filling cystometry 45–48
  overactive bladder and 44, 47–48
  post-augmentation studies 195–196
  pressure–flow studies (PFS) 49–51
  video urodynamics 50
urothelium histological changes 16
vaginal atrophy 37
vaginal prolapse see pelvic organ prolapse
  vardenafil 124–125
VICTOR study 121
video urodynamics 50
vitamin B12 deficiency 197
vitamin D3 receptor agonism 101
voiding symptoms 31–32
  hesitancy 31
  incomplete emptying 32
  poor/intermittent flow 32
  post-micturition dribble 32
  straining 31
weight management 66–67, 73